Fig. 3From: A randomized crossover trial to assess therapeutic efficacy and cost reduction of acid ursodeoxycholic manufactured by the university hospital for the treatment of primary biliary cholangitisAdverse events. Most patients did not have AE 55.88% (19/34). The majority of adverse events were with capsule 29.41% (10/34) resulted more AE compared with tablets. No patient of sequence B had AE using UDCA tablets while sequence A had adverse event in UDCA tablets and capsules 5.88% (2/34). The discontinuation due to adverse event occurred in 5.88% (2/34) of patients in the sequence B. Legend: AE = adverse eventsBack to article page